Retatrutide Approval Tracker: FDA, EMA, TGA Status (2025)

Retatrutide (LY3437943) holds promise as a powerful weight loss drug, but its retatrutide approval status remains investigational worldwide in 2026.[1] No regulatory body, including the FDA, EMA, Health Canada, or MHRA, has approved it for obesity, type 2 diabetes (T2D), or other uses.[1] Phase 3 TRIUMPH trials are ongoing,[3] with standout results like 28.7% average weight loss in TRIUMPH-4,[5] paving the way for a potential New Drug Application (NDA) submission late 2026.

What Is Retatrutide? (LY3437943 Overview)

Retatrutide is an experimental medication developed by Eli Lilly.[5] It targets obesity, T2D, obstructive sleep apnea (OSA), and related conditions.[3] Unlike approved drugs, it activates three key hormone receptors for enhanced effects.[2]

Triple Agonist Mechanism: GLP-1, GIP, and Glucagon Receptors

Retatrutide works as a triple agonist. It mimics GLP-1 and GIP, like tirzepatide, but also activates glucagon receptors.[2]

This combination boosts insulin release, slows digestion, reduces appetite, and increases energy use.[2] Early studies show it leads to greater fat loss without a weight loss plateau.[2] Eli Lilly pipeline.[5]

• GLP-1: Controls blood sugar and hunger.
• GIP: Improves insulin sensitivity.
• Glucagon: Burns fat and spares muscle.

Developer: Eli Lilly and Key Indications (Obesity, T2D, OSA)

Eli Lilly, maker of Mounjaro and Zepbound, leads retatrutide's development.[5] Main goals include chronic weight management and T2D control.[3]

Trials also test it for OSA, knee osteoarthritis pain, cardiovascular risks, and kidney issues.[3][4] Over 5,800 patients are in Phase 3 studies.[3] Dosing is once-weekly subcutaneous injection.

Comparison to Tirzepatide and Semaglutide

Retatrutide outperforms dual agonists in trials.[2] Phase 2 data: 24.2% weight loss vs. tirzepatide's ~21% and semaglutide's 15-17%.[2]

It shows better liver fat reduction and cardiometabolic benefits.[2] However, full head-to-head Phase 3 comparisons are pending. NEJM Phase 2 study.[2]

Current Retatrutide Approval Status: Not Approved Anywhere

The retatrutide approval status is clear: unapproved globally as of April 2026.[1] It is strictly investigational, available only in clinical trials.[1] No NDAs or equivalents have been filed.[1]

FDA Approval Status: Investigational, No NDA Submitted

The FDA lists retatrutide as investigational.[1] No NDA filing yet; Phase 3 data compilation continues.[1]

No Priority Review or Breakthrough Designation granted.[1] Check FDA novel drugs for updates—it's absent.[1] Is Retatrutide FDA Approved?

EMA, MHRA, and TGA: No Approvals or PDUFA Dates Set

EMA has no Marketing Authorization Application.[1] MHRA (UK) and TGA (Australia) show no approvals; trials run at local sites but no submissions.[1]

No PDUFA-like dates exist without NDAs.[1] Alignment with FDA is likely.

Global Status: No Approvals in Any Country (2026 Update)

Zero countries have approved retatrutide.[1] Databases confirm absence from approved lists worldwide.[1]

Retatrutide Clinical Trial Status: Phase 3 TRIUMPH Program

Phase 3 dominates retatrutide's approval status journey.[3] The TRIUMPH program includes seven trials (TRIUMPH-1 to -7) plus outcomes studies.[3]

Enrollment is complete or near-complete.[3] Focus: obesity, T2D, OSA, CVD, OA pain. ClinicalTrials.gov.[3]

Ongoing Phase 3 Trials: TRIUMPH-1 to TRIUMPH-7 Details

• TRIUMPH-1/2: Obesity weight loss (NCT05929066, ~2,300 patients, ends May 2026).[3]
• TRIUMPH-3: Obesity with CVD (NCT05882045, ends April 2026).[4]
• TRIUMPH-4: Knee OA with overweight (topline Dec 2025).[5]
• TRIUMPH-5/6: T2D and OSA.
• TRIUMPH-7: Weight maintenance (NCT06859268, ends 2028).
• TRIUMPH-OUTCOMES: CV/renal safety.

Doses: Up to 12mg, some 4mg maintenance.

Key Milestones: TRIUMPH-4 Topline Results (28.7% Weight Loss)

TRIUMPH-4 hit endpoints: 28.7% weight loss (71 lbs), 4.5-point pain drop, better function vs. placebo (2.1%).[5]

CV markers improved: lower cholesterol, BP down 14 mmHg.[5] Lilly press release.[5]

Completion Timeline: Late 2026-Early 2027

Primary completions span 2026.[3] Full data readout by Q4 2026.[3] Supports NDA prep.

Projected Retatrutide Approval Timelines

Analysts project NDA late 2026 after data.[1] FDA review: 10-12 months standard, 6 for priority.[1]

Retatrutide approval status hinges on trial success.

NDA Submission: Late 2026 to Q1 2027

Eli Lilly targets post-TRIUMPH completion.[5] All seven trials inform obesity/T2D filings.[3]

FDA Review and Potential Approval: 2027-2028 Projections

Optimistic: 2027 approval.[1] Realistic: 2028 launch.[1] retatrutide PDUFA date projections

Factors: Superior efficacy may speed review.

Factors Influencing Delays or Acceleration (Priority Review)

• Accelerators: >25% weight loss, clean safety.[2]
• Delays: CV signals, manufacturing issues.
• Projections vary; monitor Lilly updates.

Retatrutide Efficacy Results from Phase 2 and 3 Trials

Trials highlight retatrutide's edge.[2][5] Weight loss exceeds competitors; broad benefits seen.

Weight Loss Data: Up to 24.2% (Phase 2) and 28.7% (Phase 3)

Phase 2 (48 weeks): 24.2% at 12mg vs. 2.1% placebo.[2] 93% lost ≥10%.[2]

Phase 3 TRIUMPH-4: 28.7% at 68 weeks.[5] Sustained, dose-dependent. detailed Phase 2 results

Additional Benefits: Glycemic Control, CV Markers, Pain Reduction

• A1C drops to <6.5% in 82% (T2D Phase 2).[2]
• Lipids, BP, liver fat improved.[2]
• Knee pain: 14% pain-free vs. 4% placebo.[5]

Comparisons to Existing GLP-1 Agonists

Surpasses semaglutide (15%), tirzepatide (21%).[2] Glucagon adds fat-specific loss, potential muscle preservation.

Safety Data and Side Effects Profile

Safety mirrors GLP-1 class: manageable with titration.[2] Phase 3 data builds confidence.[5]

Common Side Effects: GI Issues (Nausea, Diarrhea) Like Semaglutide

Nausea (38-43%), diarrhea (33%), during escalation.[2] Mild-moderate, dose-related.

Similar to Mounjaro/Zepbound.[2]

Discontinuation Rates and Tolerability

6-18% quit for AEs (vs. 4% placebo).[2] Lower in maintenance dosing.[5] Well-tolerated overall.

Long-Term Safety: Pending CV and Renal Outcomes

TRIUMPH-OUTCOMES tests CV/renal.[3] Muscle preservation promising. muscle preservation benefits

No major red flags; monitor heart rate.

Legal Status and Availability: Clinical Trials Only

Retatrutide's approval status means no legal sales.[1] FDA warns against fakes.

FDA Warnings on Compounding and Online Sales

Compounding banned; not FDA-approved ingredient.[1] Warning letters issued.[1] Avoid "research" labeled products—unsafe. FDA warnings on retatrutide compounding

No Prescription or Pharmacy Access

Unavailable at pharmacies.[1] No off-label use.

How to Join Retatrutide Clinical Trials Legally

Search ClinicalTrials.gov for sites.[3] Eligibility: BMI ≥27-30, comorbidities. legal access options for retatrutide

International Retatrutide Approval Status

Global regulators trail US.[1] No approvals.

Health Canada: No NOC or DIN Assigned

Absent from Drug Product Database.[1] No Notice of Compliance.[1] Trials global, no Canada-specific NOC.

MHRA (UK): Phase 3 Trials Ongoing, Approval ~2027-2028

UK sites active (e.g., NCT05929066).[3] Submission post-FDA, approval late 2027.[1]

Other Regulators: EMA, TGA, and Global Outlook

EMA/TGA: Phase 3 only.[1] Sync with FDA; 2027-2028 possible.

Future Outlook: Commercial Projections and Risks

Retatrutide could transform markets if approved.

Peak Sales Estimates: $30B by 2031

$10B obesity, $20B T2D. Launch 2028 readiness.

Potential Risks: Safety Issues or Regulatory Hurdles

Delays from AEs, CRLs. Competition from next-gen GLP-1s.

What Happens Next for Retatrutide Approval

Q2-Q4 2026: More toplines.[5] NDA 2026.[1] Track retatrutide approval status via Lilly/FDA.

Conclusion: Stay Updated on Retatrutide Approval Status

Retatrutide's path is promising but pending Phase 3 wrap-up.[3] Current retatrutide approval status: not approved anywhere.[1] Expect updates late 2026. Consult physicians; join trials ethically. Monitor Lilly investor site and regulators for changes.[5]

FAQ

Is retatrutide FDA approved in 2026?

No, retatrutide is not FDA approved as of 2026.[1] It remains an investigational drug in Phase 3 TRIUMPH trials,[3] with no New Drug Application (NDA) submitted yet.[1] Approval is projected for late 2026 to 2028, depending on trial results.

What is the current retatrutide approval status worldwide?

Retatrutide is not approved by any major regulator, including the FDA, EMA, Health Canada, or MHRA.[1] Phase 3 trials are ongoing globally,[3] showing strong results like 28.7% weight loss in TRIUMPH-4.[5] It's only available through clinical trials.[1] The retatrutide approval status reflects its investigational phase across all regions.

When can we expect retatrutide approval?

Eli Lilly plans NDA submission in late 2026 after Phase 3 completion.[5] FDA approval could follow in 2027-2028 if data is positive,[1] though timelines may shift due to safety reviews. Priority review might speed it up due to superior weight loss data compared to existing GLP-1 drugs.[2]

Can I buy retatrutide online or get it prescribed now?

No, retatrutide is not legally available outside clinical trials.[1] The FDA warns against unapproved online sales or compounding, as they are unsafe and illegal.[1] Join trials via ClinicalTrials.gov for access—avoid any gray-market sources.[3]

What are the latest retatrutide trial results?

Phase 3 TRIUMPH-4 showed 28.7% average weight loss at 68 weeks,[5] beating prior drugs. Phase 2 trials hit up to 24.2% loss.[2] Full data from ongoing trials will support approval filings, including benefits for pain, glycemic control, and CV markers.

Is retatrutide approved by Health Canada?

No, retatrutide has no Notice of Compliance (NOC) or Drug Identification Number (DIN) from Health Canada.[1] It is investigational, with no submissions in their database.[1] Global Phase 3 trials include potential Canadian sites, but approval would likely follow FDA timelines in 2027-2028.

What is the MHRA or EMA retatrutide approval status?

Neither MHRA (UK) nor EMA has approved retatrutide.[1] Phase 3 trials are active at UK and EU sites,[3] with submissions expected post-FDA NDA (late 2027).[1] Approvals could align around 2027-2028, pending positive safety and efficacy data.

How does retatrutide compare to tirzepatide or semaglutide?

Tirzepatide (Mounjaro/Zepbound) and semaglutide (Wegovy/Ozempic) are approved, while retatrutide is not.[1] Efficacy-wise, retatrutide shows higher weight loss (up to 28.7% vs. 21% tirzepatide, 15-17% semaglutide) due to its triple-agonist action,[2][5] plus better pain reduction and metabolic benefits in trials.[2]

References

1. FDA Novel Drug Approvals (Retatrutide not listed)
2. Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, for People with Type 2 Diabetes
3. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)
4. A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight and Cardiovascular Disease (TRIUMPH-3)
5. Eli Lilly Discovery Pipeline (Retatrutide Phase 3)